Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Plus Chemoradiotherapy as Adjuvant Treatment for Postoperative Cervical Cancer
NCT06727617Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of serplulimab in Cervical Cancer (CC) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Disease-Free Survival at 1 year. Started Nov 2024; status: recruiting.
02
Drugs
serplulimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06727617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06727617.